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Connexins (Cxs) are building unit proteins of gap junctions (GJs) that are prognostic markers in carcinomas. To investigate the
role of Cx in Ewing sarcoma (EWS)/primitive neuroectodermal tumor (PNET), we examined the expression of Cx43 and Cx26
in 36 EWS/PNETs and found (1) cytoplasmic Cx43 reactivity in 28/36 (78%) cases. (2) Cx43 score was signiﬁcantly correlated
w i t ho v e r a l ls u r v i v a l( P = .025). The average scores for patients alive and dead at 3 years are 46.08 and 96.98 (P = .004) at 5 years
are 46.06 and 96.42 (P = .002). (3) Metastasis had a signiﬁcant eﬀect on the overall survival (P = .003). (4) Cytoplasmic Cx26
reactivity was detected in 2 of 36 (6%) patients who died with metastasis. Our results suggest a possible oncogenic and prognostic
role for Cx43 and Cx26 in EWS/PNET. The lack of membranous immunoreactivity suggests that the eﬀe c to fC xi nE W S / P N E T
is via a GJ function-independent mechanism.
1.Introduction
Ewing sarcoma (EWS)/primitive neuroectodermal tumor
(PNET) is an aggressive sarcoma that commonly aﬀects
children and young adults. It is primarily a tumor of bone
but may also develop in soft tissue [1]. The pathogenesis and
histogenesis of EWS/PNET is largely unknown, but the vast
majority of patients have the 11:22 EWS-FLI-1 transloca-
tion.Theprognosisofpatientswhodevelopadvanceddisease
remains poor. The current available prognostic biomarkers
for this group of tumors are very limited. Discovery of novel
biomarkers that have prognostic and predictive value for
patients with EWS/PNET would serve as guidance for the
development of novel targeted therapeutic strategies.
Connexins (Cxs) are a family of homologous proteins
that serve as the building blocks of gap junctions (GJs). GJs
permit the direct exchange of small molecules between cells.
G J sa r ep r e s e n ti na l lt y p e so fv e r t e b r a t ec e l l s ,e x c e p tr e d
blood cells, platelets, some neurons, and spermatozoids [2]
and represent a fundamental structure necessary for normal
cell function [3]. The Cx-mediated GJ communication also
playsacriticalroleinosteoblastdiﬀerentiation[3–5].Among
the 20 known Cxs, Cx43, Cx45, and Cx46 are expressed
in bone. Cx43 is the primarily expressed form and plays
majoranddiverserolesin bonedevelopment [5].Inaddition
to the important role of Cx43 in bone development and
diﬀerentiation, dysregulation of Cx expression is believed to
have a role in carcinogenesis. Cxs, especially Cx43 and Cx26,
have been shown to be associated with carcinomas of the
lung, breast, prostate, liver, stomach, and colon [6–14]. Cxs
were also shown to be involved in invasion and metastasis
of melanoma and acute leukemia [9, 13]. However, little is
known with regard to the role of Cx in sarcomas. In this
study, we examined the expression of Cx43 and Cx26 in2 Sarcoma
a series of EWS/PNET and correlated the results with various
clinicopathologic features and patient outcome in order to
explore their potential role in the biology of this group of
sarcomas.
2.MaterialsandMethods
This study was carried out in accordance with a research
protocol approved by the Scientiﬁc Review Committee of the
Moﬃtt Cancer Center and the Institutional Review Board of
the University of South Florida.
2.1. Tissue Samples and Tissue Microarray (TMA). Ar e t -
rospective review was conducted to identify cases of
EWS/PNET diagnosed between 1995 and 2007 and archived
attheDepartmentofAnatomicPathologyattheMoﬃttCan-
cer Center. All cases were reviewed and diagnosis conﬁrmed
by a sarcoma pathologist (MMB). Representative formalin-
ﬁxed, paraﬃn-embedded tumor blocks were selected for
tissue microarray (TMA) construction at the Histology Core
FacilityoftheMoﬃttCancerCenter[15].Thecorresponding
H&E slides of the TMA were reviewed to determine tissue
integrity prior to immunohistochemical testing.
2.2. Patient Data. Pertinent clinical data of patients were
compiled from two sources: (1) pathology database to
include age, sex, tumor location, tumor size, and ancillary
study results and (2) tumor registry to include treatment and
survival information. All patients were treated at the Moﬃtt
Cancer Center with neoadjuvant chemotherapy, followed
by resection. External beam radiation therapy was reserved
for resections with positive surgical margins or unresectable
disease.
2.3. Immunohistochemistry (IHC) and Image Analysis. Four-
μm-thick sections from the TMA were used for immuno-
histochemical staining for Cx43 (goat polyclonal, CXN-6,
1:250 dilution, Santa Cruz Biotechnology Inc., Santa Cruz,
CA) and Cx26 (rabbit polyclonal, 1:100 dilution, Zymed
Laboratories, San Francisco, CA). Antigen retrieval was
performed in 10 mmol/L of sodium citrate buﬀer (pH 7.6)
in a microwave oven for 4 minutes twice at 70% power level.
Endogenous peroxidase was blocked by incubation in 5%
hydrogen peroxide for 5 minutes. Nonspeciﬁc binding sites
were blocked by incubating with 2% normal horse serum
for 20 minutes. Sections were incubated with the primary
antibodies at room temperature for 60 minutes. Immunore-
activity was visualized by using the DAKO EnVision+ Sys-
tem, HRP labeled polymer on a DAKO autostainer (DAKO,
Carpinteria, CA). Both a positive and a negative control were
used according to the manufacture’s recommendation. The
controls were brain tissue. The negative control was run
without the primary antibody.
Immunoreactivity was quantitatively evaluated by auto-
mated slide scanning using the Aperio ScanScope XT (Vista,
CA) and Image Pro Plus v6.2 (Bethesda, MD) analyzing
macroalgorithms based on the intensity (0–3) and percent-
age (%) of staining. A score of 0–300 was calculated for each
case as the product of the intensity score and the percent of
immunoreactivity. Theimageanalysisresultwasthenquality
controlledbyasarcomapathologist(MMB)todeterminethe
cutoﬀ for positive verses negative stain.
2.4. Statistical Analysis. Median Cx immunostaining scores
were compared between patients with metastatic disease and
localized disease, as well as between patients alive and dead
at 3 years and 5 years using the Mann-Whitney-Wilcoxon
(MWW) test. Overall survival distributions of patients with
metastatic disease and localized disease were visualized using
the method of Kaplan-Meier curve. The log-rank test was
used to test the eﬀect of metastasis on overall survival. The
proportional hazard model was used to test the eﬀects of
median Cx immunostaining scores and metastasis on the
overall survival. The point estimation of the hazard ratio
and the P value (from the test of whether the hazard ratio
is equal to 1) was reported. In our analysis, a P-value less
than .05 was considered as being statistically signiﬁcant.
Computations were performed using the Statistical Anal-
ysis System (SAS), Version 9.2 (SAS Institute, Cary, NC)
software.
3. Results
3.1.CxExpressionPattern. TheCx43expressionisillustrated
in Figure 1. The score of Cx43 is listed in Table 1. A score
of less than 15 was considered as negative stain. Although
there is no published benchmark for the cutoﬀ for connexin,
a score of less than 15 and micr oscopically immunoreactive
inlessthan5%tumorcellswithonly1-2+intensity stainwas
deﬁned as negative. A score of 15 and microscopically 5%
tumor cells with 3+ intensity stain was considered positive.
We did not encounter a case that was less than 5% tumor
cells with 3+ stain intensity. The pathologists involved in this
studyagreedtothiscutoﬀ.Byimageanalysis,therangeofthe
immunoreactivity was from 1.24 to 160.38. Cases considered
negative ranged from no to very weak and focal immunore-
activity by microscopic examination. Whole section stains of
4 cases were done. Two were positive and 2 were negative
whichwereconsistentwiththecorrespondingTMAﬁndings.
Oneofthetwopositivecasesrevealedheterogeneousstaining
pattern. Due to the heterogeneity of the tumor, we did not
expect the two cores for each case to always be the same;
therefore, an average score was used for ﬁnal correlation
calculation. Cytoplasmic Cx43 reactivity was detected in
28/36 (78%) cases (median score 62, range 1–160). Cyto-
plasmic Cx26 reactivity was observed in 2 of 36 (6%)
cases.
3.2. Clinicopathological Correlation. The pertinent clinico-
pathological data are summarized in Table 1. Among the 36
patients, 19 were alive and 17 were dead of disease at their
followup days (median followup 410 days). Twelve (33.3%)
patients had metastasis at presentation and were analyzed
separately from the remaining localized patients due to the
diﬀerent prognoses between these groups.Sarcoma 3
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Figure 1: EWS/PNET TMA H&E and Cx43 stains. (a) Digital scan image of H&E Ewing TMA. Each patient has duplicate representative
sections of the tumor. The enlargement is an example of a tumor section which is composed of small blue round cells with ﬁbrous/hyalinized
stoma. (b) Digital scan image of Cx43 immunostain. Two examples of the tumor sections showing cytoplasmic immunoreactivity.
3.3. Statistical Analysis. The statistical analysis was done for
the entire group of patients. The median survival time for all
the patients is 1929, days (which is about 5 years) with 95%
conﬁdence interval from 701 days to inﬁnity.
WeimplementedtheCoxproportionalhazardmodeland
estimated the hazard ratio of the Cx43 score to test the eﬀect
of the score of Cx43. The estimated hazard ratio of score is
1.019, and the P-value is .004 indicating that higher score of
Cx43 corresponds to signiﬁcantly larger failure rate. Besides
using Cx43 score, we tested the eﬀect of the interpretation of
Cx43. Figure 2(a) depicts the Kaplan-Meier estimate of the
survival function of the positive and negative interpretation
groups.Thelog-ranktestgivesanonsigniﬁcantP-value .360,
which indicates that the dichotomized interpretation is not
signiﬁcant, and that given the signiﬁcance of the Cx43 score,
this dichotomization can lower the test power. Due to the
high censoring rates (46.4% for the positive and 75% for the
negative) and the limited numbers of observation (28 posi-
tive and 8 negative patients), ﬁnite interval estimates of the
two corresponding median survival times were not available.
We compared the Cx43 scores for patients alive and dead
a t3y e a r s ,a sw e l la sa tﬁ v ey e a r su s i n gt h eM W Wt e s t .T h e
two average scores of patients who were alive and dead at 3
years were 46.08 and 96.98, respectively, which were signiﬁ-
cantly diﬀerent with P-value .004. A similar result was found
for 5-year survival. The average score of patients who were
alive and dead at 5 years were 46.06 and 96.42, respectively,
which were signiﬁcantly diﬀerent with P-value .002.
Westudiedtheeﬀectofmetastasisontheoverallsurvival,
and the association between metastasis and Cx43 score.
Figure 2(b) shows the Kaplan-Meier curves for the patients
with metastatic disease and localized disease. The curve for
patients with metastasis is lower than the other at all the
time points. Comparing the overall survival distributions of
patients with and without metastasis, log-rank test gave P-
value .003 which indicates statistical signiﬁcance in metas-
tasis. The hazard ratio between patients without and with
metastasis was 0.25, with P-value .006. This result indicates
that the patient group with metastasis had signiﬁcantly
higherfailureratecomparedtothegroupwithoutmetastasis.
We further compared the distributions of Cx43 score for
patients with and without metastasis. The P-value derived
from the MWW test is .606 indicating that no signiﬁcant
diﬀerence was found in Cx43 score between patients with
and without metastasis.
We conducted multivariable analysis by including both
metastasis and Cx43 score. The hazard ratio for metastasis
is 0.29 with P-value .015. The hazard ratio for Cx43 score is
1.018 with P-value .009. The eﬀects of both metastasis and
Cx43 score in this multivariable analysis are comparable to
their eﬀects in the aforementioned univariable analyses. This
indicated that the eﬀect of metastasis on overall survival is
signiﬁcant in addition to the eﬀect of Cx43 score and vice
versa.
For the 2 cases showing Cx26 positivity, the patients died
with metastasis to lung and brain at 341 days and 211 days
after diagnosis, respectively.
4. Discussion
GJs function by transferring information between neigh-
boring cells in the form of a secondary messenger (such
as calcium) following a primary stimulus [3]. Cx43 is
ubiquitous in all cells, and it is the predominant GJ protein
in bone cells [16]. Cx43 serves both gap junction-dependent
and -independent functions and plays a signiﬁcant role in
controlling bone formation, diﬀerentiation, and develop-
ment [3–5, 16]. Furthermore, previous studies suggested
that aberrant cytoplasmic localization and disturbance of GJ
intercellular communication play an important role in car-
cinogenesis, invasion, and metastasis in some human malig-
nancies including carcinomas, melanoma, and leukemia [6–
14]. The role of Cxs (Cx43 in particular) in sarcoma remains
unknown.AlthoughafewstudiesofCx43inhumansarcoma
cell lines have been reported, which include osteosarcoma,
rhabdomyosarcoma, and ﬁbrosarcoma [17–21], there has4 Sarcoma
Table 1: The pertinent pathological, clinical, and Cx43 immunohistochemical data.
Case Sex Age Location Tumor size
(cm)
Cx43 score Cx43
interpretation
Metastasis Treatment OS VS
1 M 24 Chest wall 10.5 160.38 Positive No S, C, R 610 Dead
2 M 17 Lower lobe lung 21.5 112.45 Positive No C, R 623 Dead
3 F 72 Thigh 6 117.59 Positive No S, C, R 298 Dead
4M 2 8 P e l v i s 14 8.62 Negative Yes C, R 222 Dead
5 M 30 Thigh 17 95.83 Positive No S, C, R 2743 Alive
6F 2 8 F e m u r 12 63.19 Positive Yes S,C, R 522 Alive
7M 4 0 P e l v i s 10 18.49 Positive No S, C, R 1700 Alive
8M 1 7 P e l v i s N/A 55.05 Positive Yes C, R 1029 Dead
9M 2 4 P e l v i s 12.7 60.17 Positive No S, C, R 1067 Alive
10 M 59 Thigh 4.5 110.12 Positive Yes S, C 1624 Alive
11 F 15 Shoulder/Humerus 5.3 55.09 Positive No S, C 4036 Alive
12 M 33 Spine (T7) 1.6 140.11 Positive Yes S, C, R 209 Dead
13 F 15 Femur 3.7 126.51 Positive Yes S, C 701 Dead
14 F 57 Leg 34.5 144.65 Positive No S, C 505 Dead
15 M 12 Distal femur 11 72.41 Positive No S, C, R 5065 Alive
16 M 35 Flank 3 83.9 Positive No S, C, R 3892 Alive
17 M 58 Thigh 8 56.45 Positive Yes S, C, R 661 Alive
18 F 35 Fibula 7 5.3 Negative No S, C, R 1301 Alive
19 M 54 Chest 8 135.54 Positive No S, C, R 681 Dead
20 M 15 Ilium 7.5 78.71 Positive No S, C, R 1929 Dead
21 M 28 Rib 5 88.57 Positive No S, C, R 1553 Dead
22 F 61 Chest 7.5 73.89 Positive No S, C 364 Dead
23 M 16 Pelvis 7.5 12.71 Negative No S, C, R 1929 Alive
24 F 16 Rib 5 50.25 Positive No S, C 2233 Alive
25 M 14 Leg N/A 16.61 Positive No S, C 637 Alive
26 F 71 Uterus 11 13.07 Negative Yes S 25 Dead
27 M 29 Thigh 30 14.43 Negative No S, C, R 2743 Alive
28 F 41 Lung 8 17.25 Positive Yes S, C, R 2388 Dead
29 M 34 Chest wall 5.7 32.34 Positive No S, C 1624 Alive
30 F 67 Lung 7 109.74 Positive Yes S, C, R 341 Dead
31 F 20 Brain 1.2 1.24 Negative No S, C, R 806 Alive
32 F 16 Rib and diaphragm 5 104.5 Positive Yes S, C, R 711 Dead
33 M 58 Abdominal wall 5.5 2.42 Negative No S, C, R 1204 Live
34 M 37 Brain 2 2.94 Negative No S, R 664 Live
35 M 24 Cerebellum 1 75.33 Positive No S, R 2109 Live
36 F 47 Brain 2 55.68 Positive Yes S, C, R 211 Dead
∗S: Surgery; C: Chemotherapy; R: Radiation, OS: Overall survival rate; VS: Vital status.
not been any studies reported on the expression of Cx43
in formalin-ﬁxed and paraﬃn-embedded tissue samples of
human EWS/PNET.
Our study shows that EWS/PNET expresses cytoplasmic
Cx43 frequently (78%). A higher level of Cx43 expression
was correlated with adverse outcome and shorter survival
in EWS/PNET patients, regardless of their stage, location,
tumor size, and clinical management. In contrast to Cx43,
Cx26 was rarely detected in EWS/PNET with only 2 of 36
(6%) cases showing cytoplasmic Cx26 immunoreactivity. In
both cases, patients died with metastasis in 341 days and 211
days after diagnosis, respectively.
The ﬁnding of cytoplasmic Cx expression in EWS/PNET
is of interest. Cx is normally expressed on cell surface
as membranous proteins that build blocks of GJs which
function in regulating cell proliferation and apoptosis [8].
NormalexpressionofCxplaysimportantroleinmaintaining
normal GJ function and regulating cell proliferation [8].
Studies have shown that in carcinomas, lack of functional
intercellular connections is reﬂected by aberrant cytoplasmicSarcoma 5
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Figure 2: The Kaplan-Meier estimates of overall survival by (a) Cx43 interpretation; (b) metastasis.
accumulation of Cxs. Because of the proteins of gap junction
channels, components are stored in the cytoplasm, and
dysfunctional traﬃcking decreases the uptake of Cxs by the
cell membrane from the cytoplasm [8, 22, 23]. Since the
normal tissue counterpart of Ewing sarcoma is unknown,
this study was not able to investigate if there is a “nor-
mal” expression pattern of Cx43 in Ewing cells. However,
studies of human ﬁbrosarcoma and osteosarcoma cell lines
demonstratethattheexpression/distributionpatternofCx43
varies with diﬀerent experimental conditions suggesting that
aberrant pattern be cytoplasmic or nuclear [17–20]. The
abnormal or aberrant expression might be related to a defect
in GJ assembly associated with increased Cx synthesis and/or
Cx degradation. In addition, this abnormal or aberrant
expression seen with immunohistochemical technique is
not uncommon in other oncoproteins. For example, C-
kit is expected to be membranous staining in normal cir-
cumstance; however, cytoplasmic and globular/dot-like stain
patterns are frequently encountered on routine immunohis-
tochemical stain and biologically the same as membranous
staining [24].
In addition to its GJ-dependent function, Cx has also
been shown to have biologic functions independent of GJs
in colorectal cancer [25–28]. As Cx43 is a downstream
target of β-catenin, a key component of Wnt signaling
pathway, nuclear accumulation of β-catenin turns on several
genes including Cx43, COX-2, cyclin-D1, and PPARδ and
contributes to the carcinogenesis of colon cancer [25–28].
Cx has been shown to have a tumor suppressor role in
experimental setting in some carcinomas [7, 8], whereas it
seems to function as an oncoprotein in others [28]. Saito et
al. [21] have shown that Cx43 can suppress the proliferation
of U2OS osteosarcoma cells by increasing the level of p27
protein via posttranscriptional regulation. Krutovskikh et
al. [22] have demonstrated that negative growth control of
osteosarcoma cell by Bowman-Birk protease inhibitor from
soybean involves Cx43. Therefore, the role of Cxs in tumor
biology appears to be more complex than what was once
believed and likely multifaceted. The lack of membrane
reactivity and presence of cytoplasmic reactivity suggest that
these Cxs likely function in a GJ-independent mechanism in
EWS/PNET.
Our ﬁnding of frequent Cx43 cytoplasmic expression
in EWS/PNETs and higher expression in tumors showing a
more aggressive clinical behavior also suggests a potential
oncogenic role of Cx43 in these tumors. As most of the
EWS/PNETs in this study were conﬁrmed to have EWS-FLI1
translation, Cx43 or Cx26 expression is not aﬀected by EWS-
FLI1.Althoughthedataislimited,ourﬁndingofcytoplasmic
Cx26 expression in only two cases with distant metastasis
andpooroutcomesuggeststhatCx26cytoplasmicexpression
may be a rarer event, potentially a more advanced secondary
event in a subset of EWS/PNET.
Our study has shown that the score of Cx43 was
signiﬁcantly correlated with overall survival; however, there
was no association of Cx43 score with metastasis, probably
due to the limited sample size of 36. For our dataset, both
Cx43 score and metastasis have been proven to be important
prognostic factors for overall survival.
Our ﬁndings suggest that immunohistochemical detec-
tion of Cx might provide prognostic information in this
group of patients for whom there is very limited prognostic
biomarkers currently available. Currently, EWS is treated
uniformly with a combination chemotherapeutic regimen
without dose escalation or reduction based on presenting
features for localized disease. Intensiﬁcation of therapy
with autologous hematopoetic stem cells is being explored
in limited metastatic settings. Though the level of Cx43
cytoplasmic expression would not be proposed to change
therapy at this time, it can be further studied in larger6 Sarcoma
series as a potential prognostic marker. Understanding the
role of aberrant Cx43 expression in EWS/PNET may help
explain the ontogeny of EWS, identify an important step in
o n c o g e n e s i si nas u b s e to ft u m o r s ,a n de v e n t u a l l ys e r v ea sa
therapeutic target.
Given the important role of Cx43 in tissue development,
diﬀerentiation, and carcinogenesis, especially in bone cells,
alterations in the expression of Cx43 may inﬂuence cell-
cell communication and may serve as a potential prognostic
marker as well as a target for novel agents in Ewing sarcoma.
Given that the sample size of this study is limited (36 patients
in total), power of the statistical tests can be improved with
more patients, and the interaction eﬀects of the independent
variables can be investigated in the survival analysis as well.
More studies and larger sample sizes are needed to further
investigate the potential prognostic/predictive role of Cx in
EWS/PNET.
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